First-in-class device addresses significant unmet medical need in heart failure, modulates strength of heart muscle contraction rather than rhythm
Read more
As part of its continuing mission to provide innovative, state-of-the-art robotic-based rehabilitation solutions, Motorika will introduce the Optimal-G™ Pro, its most advanced personalized robotic gait platform, at the upcoming 2019 APTA Combined Sessions Meeting taking place Jan. 23 through Jan. 26 in Washington DC.
Read more
Royal Philips, a global leader in health technology, today announced that it has signed an agreement to acquire EPD Solutions, an innovator in image-guided procedures for cardiac arrhythmias (heart rhythm disorders)…
Read more
EPD’s Cardiac Mapping and Navigation System received CE mark approval. The system helps electrophysiologists navigate the heart by generating an accurate 3D map, while imaging and pinpointing the exact location and orientation of catheters in the heart during diagnostic and therapeutic procedures for cardiac arrhythmias. “Receiving the CE mark is a very significant milestone for […]
Read more
Impulse Dynamics announced today the first implant in the Company’s FIX-HF-5CA Continued Access Study. The FIX-HF-5CA study is a multicenter, prospective, single-arm continued access evaluation of the company’s Cardiac Contractility Modulation (CCM) device. Impulse Dynamics’ proprietary CCM technology delivers non-excitatory electric pulses to the cardiac muscle, with the potential for improved exercise capacity and quality of life.
Read more
Impulse Dynamics is pleased to announce that it has successfully completed enrollment of the 160 subjects required for its FIX-HF-5C Confirmatory Study. The FIX-HF-5C Study is a prospective, multicenter, randomized study to evaluate the safety and efficacy of cardiac contractility modulation (CCM) signals delivered by the implantable Optimizer System in patients with NYHA class III […]
Read more
Motorika’s cutting-edge robotic rehabilitation solutions to be installed in ORIGIN Polska’s state-of-the-art rehab centers in Poland.
Read more
Impulse Dynamics (USA), Inc. announced results from its FIX-HF-5C randomized, Controlled Trial of Cardiac Contractility Modulation in Heart Failure.
Read more
The China Food and Drug Administration (CFDA) has approved Impulse Dynamics’ Optimizer® system for treatment of chronic heart failure. The announcement was made on December 12, 2017 by Impulse Dynamics’ CEO, Dr. Simos Kedikoglou. “This is a major milestone for Impulse Dynamics, as it will help us offer Cardiac Contractility Modulation therapy to many patients […]
Read more
Impulse Dynamics, developer of the revolutionary Cardiac Contractility Modulation (CCM) technology for treatment of Chronic Heart Failure (CHF), announced today that the company has closed a $45 million financing round…
Read more
Friday February 3rd saw women and men across the United States dressed in shades of red, from scarlet to crimson, for National Wear Red Day.
Read more
As part of its continuing mission to provide innovative, state-of-the-art robotic-based rehabilitation solutions, Motorika will introduce the Optimal-G™ Pro, its most advanced personalized robotic gait platform, at the upcoming 2019 APTA Combined Sessions Meeting taking place Jan. 23 through Jan. 26 in Washington DC.
Read more
Motorika’s cutting-edge robotic rehabilitation solutions to be installed in ORIGIN Polska’s state-of-the-art rehab centers in Poland.
Read more
Royal Philips, a global leader in health technology, today announced that it has signed an agreement to acquire EPD Solutions, an innovator in image-guided procedures for cardiac arrhythmias (heart rhythm disorders)…
Read more
Impulse Dynamics (USA), Inc. announced results from its FIX-HF-5C randomized, Controlled Trial of Cardiac Contractility Modulation in Heart Failure.
Read more
EPD’s Cardiac Mapping and Navigation System received CE mark approval. The system helps electrophysiologists navigate the heart by generating an accurate 3D map, while imaging and pinpointing the exact location and orientation of catheters in the heart during diagnostic and therapeutic procedures for cardiac arrhythmias. “Receiving the CE mark is a very significant milestone for […]
Read more
The China Food and Drug Administration (CFDA) has approved Impulse Dynamics’ Optimizer® system for treatment of chronic heart failure. The announcement was made on December 12, 2017 by Impulse Dynamics’ CEO, Dr. Simos Kedikoglou. “This is a major milestone for Impulse Dynamics, as it will help us offer Cardiac Contractility Modulation therapy to many patients […]
Read more
Impulse Dynamics announced today the first implant in the Company’s FIX-HF-5CA Continued Access Study. The FIX-HF-5CA study is a multicenter, prospective, single-arm continued access evaluation of the company’s Cardiac Contractility Modulation (CCM) device. Impulse Dynamics’ proprietary CCM technology delivers non-excitatory electric pulses to the cardiac muscle, with the potential for improved exercise capacity and quality of life.
Read more
Impulse Dynamics, developer of the revolutionary Cardiac Contractility Modulation (CCM) technology for treatment of Chronic Heart Failure (CHF), announced today that the company has closed a $45 million financing round…
Read more
Impulse Dynamics is pleased to announce that it has successfully completed enrollment of the 160 subjects required for its FIX-HF-5C Confirmatory Study. The FIX-HF-5C Study is a prospective, multicenter, randomized study to evaluate the safety and efficacy of cardiac contractility modulation (CCM) signals delivered by the implantable Optimizer System in patients with NYHA class III […]
Read more
Friday February 3rd saw women and men across the United States dressed in shades of red, from scarlet to crimson, for National Wear Red Day.
Read moreThe Hobart Group develops and commercializes medical technologies which target top healthcare markets with significant unmet needs. Its growing portfolio of companies covers the areas of cardiology, diabetes, oncology, neurology and rehabilitation. Together, Hobart Group companies have over 200 scientists, engineers, regulatory and business experts across four continents, benefitting from clinical expertise and extensive regulatory and international market knowledge across Europe, the USA and Asia. For more information, visit www.Hobart-Group.com.
Journalists and reporters are welcome to use the following materials related to Hobart Group
Mrs. Sharon Alon
Email: Media@Hobart-Group.com
Tel: +1 347-566-6113
